Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy
pegylated liposomal doxorubicin hydrochloride
Hemic and Lymphatic Diseases+10
+ Immune System Diseases
+ Immunoproliferative Disorders
Treatment Study
Summary
Study start date: October 1, 2003
Actual date on which the first participant was enrolled.OBJECTIVES: Primary * Determine the antitumor activity of doxorubicin HCl liposome, in terms of response rate (complete response and partial response), in patients with stage IIB, IVA, or IVB recurrent or refractory mycosis fungoides. Secondary * Determine the time to progression and duration of response in patients treated with this drug. * Determine the toxicity of this drug in these patients. OUTLINE: This is an open-label, nonrandomized, multicenter study. Patients receive doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity or until a maximum cumulative anthracycline(s) dose of 400 mg/m\^2 has been reached (including anthracyclines from prior treatment). Patients are followed every 12 weeks until disease progression. PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study within 1 year.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.49 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 120 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: * Histologically confirmed mycosis fungoides * Stage IIB, IVA, or IVB * Refractory or recurrent disease after at least 2 of the following prior therapies: * Local and/or systemic steroids * Retinoids * Interferon alfa * Local carmustine * Systemic chemotherapy * Psoralen and ultraviolet A (PUVA) light therapy * No CNS involvement * No erythroderma (T4) PATIENT CHARACTERISTICS: Age * Over 18 Performance status * Karnofsky 60-100% Life expectancy * Not specified Hematopoietic * Neutrophil count at least 1,500/mm\^3 * WBC at least 2,000/mm\^3 * Platelet count at least 75,000/mm\^3 * Hemoglobin at least 10 g/dL Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT and SGPT no greater than 2.5 times ULN Renal * Creatinine no greater than 1.5 times ULN Cardiovascular * LVEF normal by echocardiography or radionuclide angiocardiography Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 2 years after study participation * No psychological, familial, sociological, or geographical condition that would preclude study compliance or follow-up * No active infection requiring specific therapy (e.g., antibiotics or anti-HIV therapy) * No other prior or concurrent primary malignant tumor except adequately treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * More than 2 weeks since prior immunotherapy Chemotherapy * See Disease Characteristics * Prior systemic chemotherapy allowed provided all of the following conditions are met: * Cumulative anthracycline dose is less than 200 mg/m\^2 * No allergy to anthracyclines * Prior methotrexate is low dose (i.e., weekly dose less than 30 mg) * More than 2 weeks since prior chemotherapy Endocrine therapy * See Disease Characteristics * No concurrent systemic steroids Radiotherapy * More than 2 weeks since prior radiotherapy Surgery * Not specified Other * Recovered from toxic effects of prior therapy, excluding alopecia * No other concurrent anticancer therapy
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 11 locations
Allgemeines Krankenhaus - Universitatskliniken
Vienna, AustriaUniversitaetsklinikum Essen
Essen, GermanyKlinikum der Friedrich-Schiller Universitaet Jena
Jena, Germany